Jason Beaman, DO, MS, MPH, FAPA
Education
Johns Hopkins University, Baltimore, MD – Master of Public Health
University of Florida, Gainesville, FL – Master of Science
Case Western Reserve University, Cleveland, OH – Fellowship
University of Oklahoma School of Community Medicine, Tulsa, OK – Residency
University of Oklahoma Health Sciences, Tulsa, OK – Internship
Oklahoma State University Center for Health Sciences, Tulsa, OK – Doctor of Osteopathic Medicine
Oklahoma State University, Stillwater, OK – Bachelor of Science
Current Role
2023 – Present: Interim Chair, School of Forensic Sciences, Oklahoma State University Center for Health Sciences
2023 – Present: Director, OSU Forensic Psychiatry Fellowship
2015 – Present: Psychiatrist, Oklahoma State University Medical Center
2014 – Present: Psychiatrist, Arkansas State Hospital
Previous Experience
2015 – 2023: Chair, Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences
2020: Medical Director, 12&12, Inc.
2018 – 2022: Executive Director of Training and Education, National Center for Wellness & Recovery
2018 – 2022: Director, Forensic Psychiatry Project ECHO
2016 – 2018: Medical Director, OSU Psychiatry Project ECHO
2015 – 2018: Program Director, OSU ODMHSAS Psychiatry Residency
2016 – 2017: Director, Behavioral Health, Oklahoma State University Health Access Network
2014: Psychiatrist, Strength of Mind
2010 – 2014: Hospitalist, Tulsa Hospitalists
2013 – 2015: Psychiatrist, The Pavilion at Williamsburg
Updates in Psychopharmacology
This presentation on Psychopharmacology Updates will explore the latest advancements and trends in the pharmacological treatment of psychiatric disorders. It will highlight the emergence of new medications, including novel antidepressants and antipsychotics that target specific neurotransmitter systems to enhance efficacy and minimize side effects. The presentation will also discuss the growing importance of pharmacogenomics, which allows for personalized treatment plans based on individual genetic profiles, improving patient outcomes. Optional: Optional presentation on emerging research on alternative treatments, such as ketamine and psychedelic-assisted therapy, will be examined, showcasing their potential benefits in treating resistant mood disorders. Attendees will gain insight into integrating these updates into clinical practice to optimize treatment strategies for their patients. All physicians should attend this program.